
Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2022, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.
Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 7, 13 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2022, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.
Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 7, 13 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
83 Pages
- Introduction
- Global Markets Direct Report Coverage
- Progressive Supranuclear Palsy – Overview
- Progressive Supranuclear Palsy – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Progressive Supranuclear Palsy – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Progressive Supranuclear Palsy – Companies Involved in Therapeutics Development
- Allyx Therapeutics Inc
- Alterity Therapeutics Ltd
- AlzProtect SAS
- Anhorn Medicines Co Ltd
- Aprinoia Therapeutics Inc
- Arvinas Inc
- Asahi Kasei Pharma Corp
- Asceneuron SA
- AZTherapies Inc
- Cortice Biosciences Inc
- Merck & Co Inc
- NeuroTau Inc
- New Amsterdam Sciences Inc
- Novartis AG
- Pinteon Therapeutics Inc
- ProMIS Neurosciences Inc
- Prothena Corp Plc
- Reata Pharmaceuticals Inc
- Retrotope Inc
- TauC3 Biologics Ltd
- TauRx Therapeutics Ltd
- Transposon Therapeutics Inc
- UCB SA
- Vaxxinity Inc
- Verge Genomics
- Voyager Therapeutics Inc
- Progressive Supranuclear Palsy – Drug Profiles
- AHT-434 – Drug Profile
- ALX-002 – Drug Profile
- Anti-tau – Drug Profile
- Antibodies to Inhibit Tau Protein for Progressive Supranuclear Palsy and Corticobasal Degeneration – Drug Profile
- APNmAb-005 – Drug Profile
- ASN-120290 – Drug Profile
- AZP-2006 – Drug Profile
- bepranemab – Drug Profile
- censavudine – Drug Profile
- deulinoleate ethyl – Drug Profile
- fasudil – Drug Profile
- Gene Modified Cell Therapy for Progressive Supranuclear Palsy – Drug Profile
- hydromethylthionine mesylate – Drug Profile
- MK-8719 – Drug Profile
- Monoclonal Antibodies to Inhibit tau Protein for Alzhiemer's Disease and Progressive Supranuclear Palsy – Drug Profile
- NAS-114 – Drug Profile
- NAS-150 – Drug Profile
- NIO-752 – Drug Profile
- omaveloxolone – Drug Profile
- PNT-001 – Drug Profile
- PRX-005 – Drug Profile
- Small Molecule to Inhibit Tau for Frontotemporal Lobar Dementia (FTLD), Progressive Supranuclear Palsy and Alzheimer's Disease – Drug Profile
- Small Molecules for Frontotemporal Dementia, Lewy Body Dementia, Progressive Supranuclear Palsy and Schizophrenia – Drug Profile
- Tau – Drug Profile
- Tau Degrader – Drug Profile
- Tau Modulator – Drug Profile
- TBL-100 – Drug Profile
- tolfenamic acid – Drug Profile
- TPI-287 – Drug Profile
- Various Tauopathies – Drug Profile
- Progressive Supranuclear Palsy – Dormant Projects
- Progressive Supranuclear Palsy – Discontinued Products
- Progressive Supranuclear Palsy – Product Development Milestones
- Featured News & Press Releases
- Apr 11, 2022: APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial
- Jan 20, 2022: Alzprotect completes recruitment for phase 2a clinical trial for AZP2006 in progressive supranuclear palsy (PSP)
- Nov 19, 2021: Announcement of enrollment of first patient in Phase IIa clinical trial of OBP-601 (Censavudine, TPN-101) in patients with progressive supranuclear palsy (PSP)
- Sep 30, 2021: Asceneuron to provide update on O-GlcNAcase Pipeline at upcoming conferences
- Aug 11, 2021: Retrotope announces completion of enrollment in phase 2 study of RT001 in patients with progressive supranuclear palsy (PSP)
- Jun 30, 2021: Retrotope announces initiation of phase 2 study of RT001 in patients with progressive supranuclear palsy (PSP)
- May 12, 2021: Voyager Therapeutics presents new preclinical data showing reduction of pathological Tau with Vectorized Anti-Tau antibody
- Feb 18, 2021: Woolsey Pharmaceuticals emerges from stealth mode to announce patients enrolled in two new CNS studies
- Jan 28, 2021: Pinteon Therapeutics announces upcoming scientific presentations
- Sep 14, 2020: Alzprotect forges ahead with first patients enrolled in Phase 2a study in progressive supranuclear palsy (PSP)
- Apr 27, 2020: US FDA allows trial to proceed for Retrotope’s RT001 in the treatment of progressive supraNuclear palsy (PSP)
- Feb 18, 2020: US FDA grants orphan drug designation for Retrotope’s RT001 in the treatment of progressive supraNuclear palsy (PSP)
- Oct 17, 2019: Arvinas to Present update on Small Molecule to Inhibit Microtubule Associated Protein Tau for Alzheimer's Disease and Progressive Supranuclear Palsy at the 2nd Targeted Protein Degradation Summit
- Sep 25, 2019: UCB presents UCB0107 anti-Tau immunotherapy phase I study results at World Movement Disorders Conference
- Sep 18, 2019: Alzprotect gets green light from French Regulator to start phase 2a clinical trial in Progressive Supranuclear Palsy (PSP)
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Progressive Supranuclear Palsy, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Universities/Institutes, 2022
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Universities/Institutes, 2022
- Table 8: Number of Products by Stage and Target, 2022
- Table 9: Number of Products by Stage and Mechanism of Action, 2022
- Table 10: Number of Products by Stage and Route of Administration, 2022
- Table 11: Number of Products by Stage and Molecule Type, 2022
- Table 12: Progressive Supranuclear Palsy – Pipeline by Allyx Therapeutics Inc, 2022
- Table 13: Progressive Supranuclear Palsy – Pipeline by Alterity Therapeutics Ltd, 2022
- Table 14: Progressive Supranuclear Palsy – Pipeline by AlzProtect SAS, 2022
- Table 15: Progressive Supranuclear Palsy – Pipeline by Anhorn Medicines Co Ltd, 2022
- Table 16: Progressive Supranuclear Palsy – Pipeline by Aprinoia Therapeutics Inc, 2022
- Table 17: Progressive Supranuclear Palsy – Pipeline by Arvinas Inc, 2022
- Table 18: Progressive Supranuclear Palsy – Pipeline by Asahi Kasei Pharma Corp, 2022
- Table 19: Progressive Supranuclear Palsy – Pipeline by Asceneuron SA, 2022
- Table 20: Progressive Supranuclear Palsy – Pipeline by AZTherapies Inc, 2022
- Table 21: Progressive Supranuclear Palsy – Pipeline by Cortice Biosciences Inc, 2022
- Table 22: Progressive Supranuclear Palsy – Pipeline by Merck & Co Inc, 2022
- Table 23: Progressive Supranuclear Palsy – Pipeline by NeuroTau Inc, 2022
- Table 24: Progressive Supranuclear Palsy – Pipeline by New Amsterdam Sciences Inc, 2022
- Table 25: Progressive Supranuclear Palsy – Pipeline by Novartis AG, 2022
- Table 26: Progressive Supranuclear Palsy – Pipeline by Pinteon Therapeutics Inc, 2022
- Table 27: Progressive Supranuclear Palsy – Pipeline by ProMIS Neurosciences Inc, 2022
- Table 28: Progressive Supranuclear Palsy – Pipeline by Prothena Corp Plc, 2022
- Table 29: Progressive Supranuclear Palsy – Pipeline by Reata Pharmaceuticals Inc, 2022
- Table 30: Progressive Supranuclear Palsy – Pipeline by Retrotope Inc, 2022
- Table 31: Progressive Supranuclear Palsy – Pipeline by TauC3 Biologics Ltd, 2022
- Table 32: Progressive Supranuclear Palsy – Pipeline by TauRx Therapeutics Ltd, 2022
- Table 33: Progressive Supranuclear Palsy – Pipeline by Transposon Therapeutics Inc, 2022
- Table 34: Progressive Supranuclear Palsy – Pipeline by UCB SA, 2022
- Table 35: Progressive Supranuclear Palsy – Pipeline by Vaxxinity Inc, 2022
- Table 36: Progressive Supranuclear Palsy – Pipeline by Verge Genomics, 2022
- Table 37: Progressive Supranuclear Palsy – Pipeline by Voyager Therapeutics Inc, 2022
- Table 38: Progressive Supranuclear Palsy – Dormant Projects, 2022
- Table 39: Progressive Supranuclear Palsy – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Progressive Supranuclear Palsy, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products by Top 10 Targets, 2022
- Figure 4: Number of Products by Stage and Top 10 Targets, 2022
- Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Routes of Administration, 2022
- Figure 9: Number of Products by Molecule Types, 2022
- Figure 10: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.